Abstract
A study of long-term survivors of pediatric Hodgkin lymphoma presented at the 2022 American Society of Hematology Annual Meeting and Exposition shows that they have an increased risk for cognitive impairment and early death when compared with individuals who never had the disease. The results suggest that they may experience accelerated aging and that assessing the biomarker for epigenetic age acceleration could be critical in addressing long-term effects of treatment on survivors of cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
